Tajiri Naoki, Quach David M, Kaneko Yuji, Wu Stephanie, Lee David, Lam Tina, Hayama Ken L, Hazel Thomas G, Johe Karl, Wu Michael C, Borlongan Cesar V
Center of Excellence for Aging & Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa, Florida, United States of America.
Neuralstem, Inc., Rockville, Maryland, United States of America.
PLoS One. 2014 Mar 10;9(3):e91408. doi: 10.1371/journal.pone.0091408. eCollection 2014.
Stroke is a major cause of death and disability, with very limited treatment option. Cell-based therapies have emerged as potential treatments for stroke. Indeed, studies have shown that transplantation of neural stem cells (NSCs) exerts functional benefits in stroke models. However, graft survival and integration with the host remain pressing concerns with cell-based treatments. The current study set out to investigate those very issues using a human NSC line, NSI-566RSC, in a rat model of ischemic stroke induced by transient occlusion of the middle cerebral artery. Seven days after stroke surgery, those animals that showed significant motor and neurological impairments were randomly assigned to receive NSI-566RSC intracerebral transplants at two sites within the striatum at three different doses: group A (0 cells/µl), group B (5,000 cells/µl), group C (10,000 cells/µl), and group D (20,000 cells/µl). Weekly behavioral tests, starting at seven days and continued up to 8 weeks after transplantation, revealed dose-dependent recovery from both motor and neurological deficits in transplanted stroke animals. Eight weeks after cell transplantation, immunohistochemical investigations via hematoxylin and eosin staining revealed infarct size was similar across all groups. To identify the cell graft, and estimate volume, immunohistochemistry was performed using two human-specific antibodies: one to detect all human nuclei (HuNu), and another to detect human neuron-specific enolase (hNSE). Surviving cell grafts were confirmed in 10/10 animals of group B, 9/10 group C, and 9/10 in group D. hNSE and HuNu staining revealed similar graft volume estimates in transplanted stroke animals. hNSE-immunoreactive fibers were also present within the corpus callosum, coursing in parallel with host tracts, suggesting a propensity to follow established neuroanatomical features. Despite absence of reduction in infarct volume, NSI-566RSC transplantation produced behavioral improvements possibly via robust engraftment and neuronal differentiation, supporting the use of this NSC line for stroke therapy.
中风是导致死亡和残疾的主要原因,治疗选择非常有限。基于细胞的疗法已成为中风的潜在治疗方法。事实上,研究表明,神经干细胞(NSCs)移植在中风模型中具有功能益处。然而,移植物存活以及与宿主的整合仍然是基于细胞治疗的紧迫问题。当前研究着手使用人神经干细胞系NSI-566RSC,在大脑中动脉短暂闭塞诱导的缺血性中风大鼠模型中研究这些问题。中风手术后7天,那些表现出明显运动和神经功能障碍的动物被随机分配在纹状体内的两个部位接受三种不同剂量的NSI-566RSC脑内移植:A组(0个细胞/微升)、B组(5000个细胞/微升)、C组(10000个细胞/微升)和D组(20000个细胞/微升)。从移植后7天开始,每周进行行为测试,持续至移植后8周,结果显示移植的中风动物的运动和神经功能缺损呈剂量依赖性恢复。细胞移植8周后,通过苏木精和伊红染色进行的免疫组织化学研究显示,所有组的梗死面积相似。为了识别细胞移植物并估计体积,使用两种人特异性抗体进行免疫组织化学:一种检测所有人细胞核(HuNu),另一种检测人神经元特异性烯醇化酶(hNSE)。在B组的10只动物中有10只、C组的9/10和D组的9/10中证实有存活的细胞移植物。hNSE和HuNu染色显示移植的中风动物中的移植物体积估计相似。胼胝体内也存在hNSE免疫反应性纤维,与宿主束平行走行,表明有遵循既定神经解剖特征的倾向。尽管梗死体积没有减小,但NSI-566RSC移植可能通过强大的植入和神经元分化产生了行为改善,支持将这种神经干细胞系用于中风治疗。